- Home
- ANEB vs NSPR Comparison
ANEB vs NSPR Comparison
Compare ANEB & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- NSPR
- Stock Information
- Founded
- ANEB 2020
- NSPR 2005
- Country
- ANEB United States
- NSPR United States
- Employees
- ANEB N/A
- NSPR N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- ANEB Health Care
- NSPR Health Care
- Exchange
- ANEB Nasdaq
- NSPR Nasdaq
- Market Cap
- ANEB 90.4M
- NSPR 101.8M
- IPO Year
- ANEB 2021
- NSPR N/A
- Fundamental
- Price
- ANEB $2.45
- NSPR $2.42
- Analyst Decision
- ANEB Buy
- NSPR Strong Buy
- Analyst Count
- ANEB 2
- NSPR 2
- Target Price
- ANEB $8.00
- NSPR $4.50
- AVG Volume (30 Days)
- ANEB 127.6K
- NSPR 78.7K
- Earning Date
- ANEB 11-12-2025
- NSPR 11-11-2025
- Dividend Yield
- ANEB N/A
- NSPR N/A
- EPS Growth
- ANEB N/A
- NSPR N/A
- EPS
- ANEB N/A
- NSPR N/A
- Revenue
- ANEB N/A
- NSPR $7,066,000.00
- Revenue This Year
- ANEB N/A
- NSPR $7.48
- Revenue Next Year
- ANEB N/A
- NSPR $104.39
- P/E Ratio
- ANEB N/A
- NSPR N/A
- Revenue Growth
- ANEB N/A
- NSPR 7.60
- 52 Week Low
- ANEB $0.80
- NSPR $1.99
- 52 Week High
- ANEB $3.42
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ANEB 52.56
- NSPR 49.10
- Support Level
- ANEB $2.33
- NSPR $2.37
- Resistance Level
- ANEB $2.58
- NSPR $2.45
- Average True Range (ATR)
- ANEB 0.16
- NSPR 0.07
- MACD
- ANEB -0.00
- NSPR -0.00
- Stochastic Oscillator
- ANEB 72.34
- NSPR 44.00
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.